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Prognostic Scores in Patients with Brain Metastases from
Non-small Cell Lung Cancer
Carsten Nieder, MD,*† Roy M. Bremnes, MD,†‡ and Nicolaus H. Andratschke, MD§
Introduction: Prognostic scores might be useful tools in both
clinical practice and clinical trials, where they can be used as
stratification parameter. The five available scores for the general
population of patients with brain metastases have never been tested
specifically in patients with non-small cell lung cancer (NSCLC).
No comparison to the two NSCLC-specific scores has been made
either. Hence, it remains unclear which score is most appropriate for
these patients.
Methods: We evaluated seven previously published prognostic
scores in a group of 183 patients with brain metastases from
NSCLC. All patients had been treated outside of clinical studies with
whole brain radiotherapy with or without radiosurgery or surgical
resection.
Results: The three scores with significant prognostic impact were
the recursive partitioning analysis classes, the basic score for brain
metastases, and the graded prognostic assessment (GPA) score. All
three score systems were developed in a general population of
patients with brain metastases. The GPA score performed better than
the others. In this four-tiered system, the 1-year survival was 43, 20,
8, and 0%, respectively.
Conclusion: Three prognostic scoring models describe the survival
of patients with brain metastases from NSCLC to a satisfactory
degree. In the current patient population, GPA performs better than
the others. The two NSCLC-specific scores were developed in
radiosurgery-treated populations, and their prognostic impact in a
general NSCLC population seems limited.
Key Words: Non-small cell lung cancer, Brain metastases, Radio-
therapy, Prognosis.
(J Thorac Oncol. 2009;4: 1337–1341)
Patients with non-small cell lung cancer (NSCLC) have ahigh risk for development of brain metastases. Factors
such as increasing primary tumor size, advanced lymph node
stage, and nonsquamous histology influence the likelihood of
brain involvement. Over the last years, increasing efforts
have been made to comprehend and use prognostic indicators
in patients with brain metastases from NSCLC. In principle,
the results of such analyses can be used to create prognostic
scores, which might support decision making and treatment
recommendations. The best known scores, such as the recur-
sive partitioning analysis (RPA) classes,1 the score index for
radiosurgery (SIR),2 and the basic score for brain metastases
(BSBM),3 were created from databases containing between
65 and 1200 patients with brain metastases from a variety of
primary tumors. Thus, variable proportions of these patients
actually had primary NSCLC. The same holds true for two
newly developed scores published in 2008.4,5 Therefore, it is
necessary to examine the clinical value of these prognostic
scores in NSCLC patients and to compare their performance
with the two recently developed NSCLC-specific scores.6,7
The purpose of this study was to analyze all seven available
scores in a well-defined population of NSCLC patients
treated for brain metastases outside of clinical trials. With
regard to treatment approach with whole brain radiotherapy
(WBRT) with or without local measures, the current cohort of
patients is comparable to the one examined by the Radiation
Therapy Oncology Group in their recent analysis of RPA,
SIR, BSBM, and graded prognostic assessment (GPA) score.4
This large analysis confirmed the prognostic value of scores
developed in small radiosurgery-treated patient groups, e.g.,
SIR and BSBM, in the general patient population.
PATIENTS AND METHODS
We used a previously described brain metastasis data-
base, which contains information on patients treated with
WBRT (typically 30 Gy/10 fractions) with or without surgery
or radiosurgery (14% of patients had received additional
surgery or radiosurgery).8,9 This database has been expanded
and updated for comparison of seven prognostic brain me-
tastasis scores (overview shown in Table 1). The Rotterdam
score10 could not be evaluated because of the lack of sufficient
data on corticosteroid effects in the current patient group. For
inclusion in this retrospective study, a histologic diagnosis of
NSCLC was required. The patient characteristics (n 183) and
the percentage of missing values, e.g., for lesion number and
volume are shown in Table 2. Because of missing data on one
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or two score items, some patients had to be excluded for
analysis of the respective score. Thus, a minimum of 135
patients were available for each of the analyses. At the time
of analysis, eight patients were alive (follow-up 2.5–8
months, median 4 months). The Kaplan-Meier method was
used to generate actuarial survival curves. For statistical
comparisons, the log-rank test was used. A p value less than
0.05 was considered statistically significant.
RESULTS
Of seven scores, four failed to statistically significantly
discriminate prognostically between the groups. Among these
were the two newly described NSCLC-specific scores. The
problem with the Rades et al.,5 Golden et al.,7 and Chao et al.6
score was the lack of significant survival differences between
the two groups with intermediate prognosis. This is illustrated
in Table 3. The Golden et al. score was also tested in its
general population form, i.e., with age, extracranial metasta-
ses, and Karnofsky performance status (KPS) as the three
parameters.7 However, replacing number of brain metastases
by KPS did not alter the results in the current analysis of
patients with NSCLC. Regarding the SIR score,2 the lack of
improved survival in the favorable group might be related to
sample size. With only four patients, no definitive conclusion
can be drawn. The score systems which divided the patient
group in subsets with significantly different prognosis were
RPA (n  159),1 BSBM (n  135),3 and GPA (n  173;
Figures 1–3; Table 4).4 The GPA score separated the four
groups better than BSBM. In this system, 1-year survival was
43, 20, 8, and 0%, respectively.
DISCUSSION
WBRT continues to represent an important palliative
treatment option for patients with brain metastases from
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FIGURE 1. Actuarial survival curves according to the recur-
sive partitioning analysis (RPA) score (p  0.05), n  10 in
class I, 90 in class II, and 59 in class III.
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FIGURE 2. Actuarial survival curves according to the basic
score for brain metastases (BSBM) score (p  0.05), n  9 in
class I, 32 in class II, 61 in class III, and 33 in class IV.
TABLE 2. Patient Characteristics (n  183)
Median age, range 61 yr, 36–85
Median KPS, range 70, 30–100
Median time intervala, range 3 mo, 0–51
% Single brain metastasis vs. multiple, unknown 42 vs. 54, 4
Median volume of the largest lesion, unknown 15 mL, 4%
% Without extracranial metastases vs. with
extracranial metastases, unknown
50 vs. 48, 2
% With controlled vs. uncontrolled primary tumor,
unknown
19 vs. 59, 22
% Female vs. male gender 22 vs. 78
% Squamous vs. adenocarcinoma vs. large cell
carcinomab
31 vs. 29 vs. 6
a From lung cancer diagnosis to brain metastases.
b In addition, 4% were classified as mixed type and 30% as non-small cell not
otherwise specified.
KPS, Karnofsky performance status.
TABLE 3. The Score Systems Which Failed to Achieve Statistically Significant Discrepancy with Respect to Prognostic Impact
(p  0.05 with Log-Rank Test of Kaplan-Meier Survival Curves)
SIR2 Rades et al.5 Chao et al.6 Golden et al.7
Score 8–10 4–7 1–3 17–18 14–16 11–13 9–10 I II III IV I II III IV
Patients, n (%) 4 (3) 103 (68) 45 (30) 38 (22) 62 (28) 49 (36) 25 (14) 12 (7) 34 (19) 79 (42) 55 (31) 52 (30) 70 (40) 45 (26) 7 (4)
Median survival (mo) 6.3 3.3 1.6 5.0 2.5 1.6 1.3 6.1 3.9 2.8 1.9 3.5 2.3 2.1 1.6
6-Mo survival (%) 50 29 4 50 21 13 0 50 44 29 7 37 19 21 0
1-Yr survival (%) 0 11 0 27 4 4 0 33 9 10 4 22 3 2 0
SIR, score index for radiosurgery.
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NSCLC. Sequential systemic chemotherapy seems to contrib-
ute to improved survival, especially in patients with good
performance status.11 Besides performance status, the ab-
sence of neurologic symptoms might predict for better sur-
vival.12 However, none of the published prognostic models
has included this factor. The fact that a significant percentage
of the patients with brain metastases from NSCLC have a very
limited survival after WBRT suggests that accurate survival
prediction models should help to avoid overtreatment.13
Established prognostic scores, such as RPA, BSBM,
SIR and GPA, were developed in the general population of
patients with brain metastases. Thus, only a limited propor-
tion of patients had NSCLC. However, multivariate analyses
in NSCLC populations confirmed the prognostic impact of
performance status, age, and extracranial metastases,14 which
are important components of most scores. One can therefore
expect that these brain metastasis scores will have a more or
less pronounced prognostic impact on patients with NSCLC.
The prognostic impact of the three-tiered RPA score was
previously confirmed in two NSCLC patient populations by
Gu¨lbaçs et al.15 and Rodrigus et al.16 However, survival in the
most unfavorable class III (defined by KPS 70) is quite
variable, with 40 to 50% of patients dying within 2 months,
but 10 to 15% surviving for more than 6 months. Making
treatment decisions solely on the basis of KPS seems to be
inadequate. Factors such as extracranial disease status and extent
of brain involvement should also be considered. Therefore, it
seems justified to look for improved prognostic models.
In the recent literature, there is a trend toward four-
tiered scores such as GPA and BSBM. The current analysis
confirms that both these score systems succeed in splitting a
NSCLC patient group with brain metastases into four prog-
nostically different subgroups. This information might help in
deciding whether surgery and radiosurgery should be consid-
ered. Both therapeutic measures were found to improve
survival in prognostically better patients with brain metasta-
ses amenable to these procedures.17–19 Given the survival
curves derived from the current analysis, patients with brain
metastases from NSCLC, primarily treated with WBRT out-
side of clinical trials, have inferior survival when compared
with others. As shown in Table 4, their prognosis is signifi-
cantly worse than that of the general population of patients
with brain metastases. Regarding the methods of the current
study, it should be noted that a retrospective analysis was
performed and that the patients had been treated over more
than a decade. Ideally, the sample size would have been
larger than 183 patients. Because of missing data, e.g., on
primary tumor control, some patients had to be excluded for
analysis of the respective score. Thus, varying numbers of
patients were available for each of the analyses. However,
previous studies on prognostic models can also be criticized
for this weakness. The recently developed NSCLC-specific
scores performed worse than RPA, BSBM, and GPA in the
current study. One of the reasons might be that radiosurgery
was the backbone of treatment in the studies that arrived at
these two scores. In other words, these were selected groups
of patients, which differ from the general population of
NSCLC brain metastases. In conclusion, this analysis favors
the use of the GPA score in unselected patients with brain
metastases from NSCLC.
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